239 reports of this reaction
2.1% of all CABOTEGRAVIR reports
#9 most reported adverse reaction
PRODUCT USE IN UNAPPROVED THERAPEUTIC ENVIRONMENT is the #9 most commonly reported adverse reaction for CABOTEGRAVIR, manufactured by ViiV Healthcare Company. There are 239 FDA adverse event reports linking CABOTEGRAVIR to PRODUCT USE IN UNAPPROVED THERAPEUTIC ENVIRONMENT. This represents approximately 2.1% of all 11,616 adverse event reports for this drug.
Patients taking CABOTEGRAVIR who experience product use in unapproved therapeutic environment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT USE IN UNAPPROVED THERAPEUTIC ENVIRONMENT is a less commonly reported adverse event for CABOTEGRAVIR, but still significant enough to appear in the safety profile.
In addition to product use in unapproved therapeutic environment, the following adverse reactions have been reported for CABOTEGRAVIR:
PRODUCT USE IN UNAPPROVED THERAPEUTIC ENVIRONMENT has been reported as an adverse event in 239 FDA reports for CABOTEGRAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT USE IN UNAPPROVED THERAPEUTIC ENVIRONMENT accounts for approximately 2.1% of all adverse event reports for CABOTEGRAVIR, making it a notable side effect.
If you experience product use in unapproved therapeutic environment while taking CABOTEGRAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.